Neurocrine Biosciences (NBIX) Net Margin (2010 - 2026)

Neurocrine Biosciences has reported Net Margin for 16 years, with the latest figure at 24.3% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 2292.0% year-over-year to 24.3%; the trailing twelve-month figure through Mar 2026 stood at 21.55% (up 888.0% YoY), and the FY2025 full-year result was 16.73%, up 224.0% from the prior year.
• Net Margin for Q1 2026 stood at 24.3%, up from 19.08% in the prior quarter.
• The five-year high for Net Margin was 28.67% in Q4 2023, with the low at 84.5% in Q2 2022.
• Historically, Net Margin has averaged 8.88% across 5 years, with a median of 16.66% in 2023.
• Annual changes were most pronounced in 2022 — Net Margin tumbled 9914 bps — and 2023, when it soared 10560 bps.
• Neurocrine Biosciences' Net Margin stood at 21.6% in 2022, then surged by 33 bps to 28.67% in 2023, then sank by 43 bps to 16.43% in 2024, then climbed by 16 bps to 19.08% in 2025, then rose by 27 bps to 24.3% in 2026.
• The last three Net Margin figures came in at 24.3% (Q1 2026), 19.08% (Q4 2025), and 26.36% (Q3 2025), per Business Quant data.